Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

In the latest trading session, Novo Nordisk (NVO) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a ...

Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising ...

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs.

TEM surges 91.8% YTD on rapid AI-healthcare growth, while NVDA fuels the sector with cutting-edge infrastructure and partnerships.

Tempus AI TEM and NVIDIA NVDA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing ...

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

AbbVie ABBV holds a leadership position in the neuroscience space, which encompasses blockbuster medications such as Botox ...

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered quantum computer to boost technological development in the Nordic ...